Department of Systems Biology, George Mason University, Fairfax, Virginia.
Department of Neuroscience, INOVA Health System, Fairfax, Virginia.
Mol Genet Genomic Med. 2019 Aug;7(8):e737. doi: 10.1002/mgg3.737. Epub 2019 Jul 3.
Aneurysmal subarachnoid hemorrhage (aSAH) has high fatality and permanent disability rates due to the severe damage to brain cells and inflammation. The SERPINE1 gene that encodes PAI-1 for the regulation of tissue plasminogen activator is considered an important therapeutic target for aSAH.
Six SNPs in the SERPINE1 gene (in order of rs2227631, rs1799889, rs6092, rs6090, rs2227684, rs7242) were investigated. Blood samples were genotyped with Taqman genotyping assays and pyrosequencing. The experiment-wide statistically significant threshold for single marker analysis was set at p < 0.01 after evaluation of independent markers. Haplotype analysis was performed in Haplo.stats package with permutation tests. Bonferroni correction for multiple comparison in dominant, additive, and recessive model was applied.
A total of 146 aSAH patients and 49 control subjects were involved in this study. The rs2227631 G allele is significant (p = 0.01) for aSAH compared to control. In aSAH group, haplotype analysis showed that G5GGGT homozygotes in recessive model were associated with delayed cerebral ischemia (p < 0.01, Odds Ratio = 5.14, 95% CI = 1.45-18.18), clinical vasospasm (p = 0.01, Odds Ratio = 4.58, 95% CI = 1.30-16.13), and longer intensive care unit stay (p = 0.01). By contrast, the G5GGAG carriers were associated with less incidence of cerebral edema (p < 0.01) and higher Glasgow Coma Scale (p < 0.01). The A4GGGT carriers were associated with less incidence of severe hypertension (>140/90) (p < 0.01).
The results suggested an important regulatory role of the SERPINE1 gene polymorphism in clinical outcomes of aSAH.
由于脑细胞严重损伤和炎症,蛛网膜下腔出血(aSAH)的病死率和永久性残疾率较高。编码组织纤溶酶原激活物抑制剂(PAI-1)的 SERPINE1 基因被认为是 aSAH 的重要治疗靶点。
对 SERPINE1 基因中的 6 个 SNP(rs2227631、rs1799889、rs6092、rs6090、rs2227684、rs7242)进行了研究。采用 Taqman 基因分型检测和焦磷酸测序法对血样进行基因分型。通过独立标志物评估,将单标记分析的实验范围显著阈值设定为 p < 0.01。采用 Haplo.stats 软件包进行单体型分析,并进行置换检验。在显性、加性和隐性模型中,对多重比较进行了 Bonferroni 校正。
本研究共纳入 146 例 aSAH 患者和 49 例对照。与对照组相比,rs2227631 的 G 等位基因在 aSAH 中显著(p = 0.01)。在 aSAH 组中,隐性模型中的 G5GGGT 纯合子与迟发性脑缺血(p < 0.01,优势比= 5.14,95%置信区间= 1.45-18.18)、临床血管痉挛(p = 0.01,优势比= 4.58,95%置信区间= 1.30-16.13)和重症监护病房停留时间延长(p = 0.01)有关。相比之下,G5GGAG 携带者与脑水肿发生率较低(p < 0.01)和格拉斯哥昏迷量表评分较高(p < 0.01)有关。A4GGGT 携带者与严重高血压(>140/90)发生率较低有关(p < 0.01)。
研究结果表明,SERPINE1 基因多态性在 aSAH 临床转归中具有重要的调节作用。